Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia
Article 2006 en
Authors
RR
Rosemarijn Renckens
JR
Joris J. T. H. Roelofs
PB
Peter I. Bonta
Abstract
1 min read
Abstract Plasminogen activator inhibitor type-1 (PAI-1) levels are consistently elevated in patients with severe pneumonia and sepsis and highly predictive for an unfavorable outcome. In addition, pneumonia is associated with strongly elevated PAI-1 levels in the pulmonary compartment. However, whether PAI-1 causally affects antibacterial host defense in vivo remains unknown. We report here that pneumonia caused by the common respiratory pathogen Klebsiella pneumoniae is associated with local production of PAI-1 in the lungs of wild-type mice. PAI-1 deficiency impaired host defense as reflected by enhanced lethality and increased bacterial growth and dissemination in mice with a targeted deletion of the PAI-1 gene. Conversely, transgenic overexpression of PAI-1 in the lung using a replication-defective adenoviral vector markedly improved host defense against Klebsiella pneumonia and sepsis. PAI-1 deficiency reduced accumulation of neutrophils in the lungs during pneumonia, whereas PAI-1 overexpression in healthy lungs resulted in neutrophil influx, suggesting that PAI-1 protects the host against Klebsiella pneumonia by promoting neutrophil recruitment to the pulmonary compartment. These data demonstrate for the first time that PAI-1 is essential for host defense against severe Gram-negative pneumonia.
Anita W. Rijneveld, Sandrine Florquin, Paul Bresser, Marcel Levi, Vivian de Waard, Roger Lijnen, Jaring S. van der Zee, Peter Speelman, Peter Carmeliet, Tom van der Poll
Dana C. Blok, Miriam H. P. van Lieshout, Arie J. Hoogendijk, Sandrine Florquin, Onno J. de Boer, Cecília Garlanda, Alberto Mantovani, Cornelis van’t Veer, Alex F. de Vos, Tom van der Poll
Rosemarijn Renckens, Joris J. T. H. Roelofs, Sandrine Florquin, Alex F. de Vos, Jennie M. Pater, H.R. Lijnen, Peter Carmeliet, Cornelis van ‘t Veer, Tom van der Poll
Discussion(0)
No comments yet. Be the first to comment.